We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

63 hedge funds and large institutions have $160M invested in Syndax Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

100% more capital invested

Capital invested by funds: $79.8M → $160M (+$80.1M)

73% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 11

11% more funds holding

Funds holding: 57 → 63 (+6)

2.73% more ownership

Funds ownership: 61.15% → 63.89% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
63
Holders Change
+6
Holders Change %
+10.53%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
19
Reduced
11
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$14.8M
2
HIM
Hillhouse Investment Management
Cayman Islands
+$2.55M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$2.48M
4
AG
Artal Group
Luxembourg
+$2.08M
5
Millennium Management
Millennium Management
New York
+$2.05M

Top Sellers

1
O
OrbiMed
New York
-$2.83M
2
EC
EcoR1 Capital
California
-$2.48M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.39M
4
Jennison Associates
Jennison Associates
New York
-$672K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$546K
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
26
Kornitzer Capital Management
Kansas
$506K – – –
EC
27
EcoR1 Capital
California
$484K -$2.48M -238,561 -87%
MCIM
28
Meadow Creek Investment Management
Georgia
$474K – – –
Deutsche Bank
29
Deutsche Bank
Germany
$449K +$313K +30,108 +1,102%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$401K +$92K +8,861 +44%
PCM
31
Prelude Capital Management
New York
$394K +$298K +28,742 New
EP
32
Elkfork Partners
Oregon
$390K – – –
OC
33
Oppenheimer & Co
New York
$365K +$276K +26,594 New
TCIM
34
TIAA CREF Investment Management
New York
$315K +$63.3K +6,091 +36%
PPA
35
Parametric Portfolio Associates
Washington
$311K -$4.91K -473 -2%
GHCM
36
Glen Harbor Capital Management
California
$306K – – –
TI
37
Trexquant Investment
Connecticut
$283K +$214K +20,595 New
NA
38
Neuburgh Advisers
California
$223K – – –
CWG
39
C WorldWide Group
Denmark
$163K +$124K +11,900 New
NI
40
Numeric Investors
Massachusetts
$152K +$115K +11,057 New
Charles Schwab
41
Charles Schwab
California
$139K – – –
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$133K -$1.04K -100 -1%
TA
43
Teachers Advisors
New York
$101K – – –
Barclays
44
Barclays
United Kingdom
$83K +$3.16K +304 +5%
JP Morgan Chase
45
JP Morgan Chase
New York
$53K -$65.6K -6,322 -62%
AIG
46
American International Group
New York
$40K +$1.99K +192 +7%
NFA
47
Nationwide Fund Advisors
Ohio
$39K – – –
Creative Planning
48
Creative Planning
Kansas
$27K +$20.8K +2,000 New
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$25K +$10 +1 +0.1%
Wells Fargo
50
Wells Fargo
California
$23K – – –
1
2
3

SNDX Hedge Fund Activity: Q1 2017 in Review

63 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2017, worth a combined $160M — up 100% from $79.8M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new SNDX positions and 3 closed out — a net gain of 12 holders — while 19 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $14.8M. The largest seller was OrbiMed, cutting an estimated $2.83M.

  • 63 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2017, up from 57 in Q4 2016.
  • Funds reported $160M of Syndax Pharmaceuticals stock for Q1 2017, up 100% quarter-over-quarter.
  • 15 funds opened new Syndax Pharmaceuticals positions in Q1 2017 and 3 closed out, a net change of +12 holders.
  • The largest Syndax Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $14.8M added.
  • The largest Syndax Pharmaceuticals seller in Q1 2017 was OrbiMed, an estimated $2.83M sold.

Based on aggregated 13F filings for Q1 2017.